Regulatory T cells and effector T cells via antigen-presenting dendritic cells

This entry describes a complex immunological axis involving the interaction between antigen-presenting dendritic cells (DCs), regulatory T cells (Tregs), and effector T cells (Teffs), rather than a single molecular target (Nature Reviews Immunology, 2019). Dendritic cells serve as the primary orchestrators of the adaptive immune response by presenting antigens via the Major Histocompatibility Complex (MHC) and providing critical co-stimulatory or co-inhibitory signals such as CD80 and CD86 (PubChem). Regulatory T cells function to maintain self-tolerance and suppress excessive immune responses, often by competing with effector T cells for access to DCs or by depleting local IL-2 (PubMed, PMID: 30108312). Effector T cells are responsible for mounting active immune responses against pathogens or tumor cells upon activation by DCs (Frontiers in Immunology, 2021). Therapeutic strategies targeting this axis often focus on specific molecular checkpoints such as CTLA-4 (targeted by Ipilimumab) or PD-1 (targeted by Pembrolizumab) to shift the balance between suppression and activation (NIH, StatPearls). Because this entry encompasses a multi-cellular process and multiple distinct molecular interactions, it does not constitute a single druggable target but rather a therapeutic pathway.

Other names

Treg-Teff-DC axisDendritic cell-mediated T cell regulationImmune synapse regulationT cell priming pathwayTreg/Teff balance

Modulation of the immune synapse through the targeting of co-stimulatory and co-inhibitory receptors to alter the balance between regulatory and effector T cell activity.